<DOC>
	<DOCNO>NCT02743780</DOCNO>
	<brief_summary>The purpose study determine clinical profile topical-ocular MGV354 merit development indication lower intraocular pressure ( IOP ) .</brief_summary>
	<brief_title>A Three Part Study MGV354 Ocular Hypertension Glaucoma</brief_title>
	<detailed_description>Part 1 evaluate safety tolerability single ascending dos MGV354 compare placebo healthy male female subject . Part 2 evaluate safety tolerability MGV354 multiple ascend dose design ( two high tolerate dos Part 1 ) compare placebo administer 7 day patient ocular hypertension glaucoma . Part 3 explore safety , tolerability efficacy single dose level MGV354 ( maximum tolerate dose ) compare placebo administer 7 day patient ocular hypertension glaucoma .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma , Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<criteria>Documented informed consent . Part 1 : 18 70 year age ; Parts 2 3 : 18 year age old ; Able communicate well investigator understand comply requirement study ; Body Mass Index ( BMI ) 18 39 ; In case contact lens wear , willing remove lenses 30 minute first assessment end study . Corrective spectacle may wear need . Sitting vital sign ( systolic diastolic blood pressure pulse rate ) within normal range specify protocol ; Part 1 ( Healthy Volunteers ) : In good health determine past medical history , physical examination , vital sign , electrocardiogram , laboratory test screen . Parts 2 3 ( Patients ) : Diagnosed openangle glaucoma confirm ocular hypertension ; mean IOP measurement least one eye washout specify protocol Other protocolspecified inclusion criterion may apply . Exclusion criterion : History hypersensitivity study drug drug similar chemical class ; History current presence clinically significant ECG abnormality arrhythmias ; History malignancy organ system ( localize basal cell carcinoma skin insitu cervical breast cancer ) , treat untreated , within past 5 year ; Known clinical history heart failure , myocardial infarction , stroke ; Exposure four week precede Screening visit topical , inhaled , systemic corticosteroid ; Angle grade less Grade 2 either eye ; Any abnormality , include corneal thickness &gt; 620 micron , prevent reliable applanation tonometry ; Pregnant lactate woman woman childbearing potential ; Sexually active male must agree use condom intercourse take drug 6 day stop MGV354 medication father child period ; Positive HIV , Hepatitis B Ag Hepatitis C Ab test result Screening ; Abnormal liver function test ; History presence impair renal function ; Part 1 ( Healthy Volunteers ) : Use NEW prescription drug herbal supplement within four ( 4 ) week prior initial dosing , and/or NEW overthecounter ( OTC ) medication , dietary supplement ( vitamin include ) within two ( 2 ) week prior initial dosing . Parts 2 3 ( Patients ) : Patients specific disease condition ( ) relate openangle glaucoma ocular hypertension ; patient safely discontinue use topical ocular and/or systemic IOPlowering medication accord protocolspecified Washout Schedule ; patient ocular disease condition specify protocol ; patient take certain medication specify protocol ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Ocular Hypertension</keyword>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>POAG</keyword>
	<keyword>Glaucoma</keyword>
</DOC>